

ATTORNEY DOCKET NO. PU3517

Form PTO-1595

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

RECORDATION FORM COVER SHEET
PATENTS ONLY

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office Assignment

Branch at (703) 306-5995 on October 23, 2003 by

Admin's name here: Elaine Martens

Sign: Elaine Martens

Commissioner of Patents. Please record the attached original documents or copy thereof.

<p>1. Name of conveying party(ies)</p> <p>Pascal Maurice Charles PIANETTI</p> <p>Additional names of conveying party(ies) attached? <input type="checkbox"/> yes <input checked="" type="checkbox"/> no</p>	<p>2. Name and address of receiving party(ies)</p> <p>SMITHKLINE BEECHAM CORPORATION One Franklin Plaza Philadelphia, Pennsylvania 19101 USA</p> <p>Additional name(s) and addresses attached?0 <input type="checkbox"/> yes <input checked="" type="checkbox"/> no</p>
---	---

3. Description of the interest conveyed:

<input checked="" type="checkbox"/> Assignment, please record and return	<input type="checkbox"/> Merger
<input type="checkbox"/> Security Agreement	<input type="checkbox"/> Change of Name
<input type="checkbox"/> Other	

Execution date of Assignment : **February 22, 2002**

4. Application number(s) or patent number(s). Additional Sheets attached? Yes No

A. Patent Application No.(s) 10/070,084 filed March 7, 2002	B. Patent No.(s)
---	------------------

If this document is being filed together with a new application, the execution date of the application is

<p>5. Name and address of party to whom correspondence concerning documents should be mailed:</p> <p>6. David J. Levy GlaxoSmithKline Corporate Intellectual Property-MAI-B475 Five Moore Drive P.O. Box 13398 Research Triangle Park, NC 27709-3398</p>	<p>6. Total number of applications and patents involved <u>1</u>.</p> <p>7. Total Fee (37 C.F.R. 3.41) \$40.00</p> <p>8. Please charge this fee to deposit account No. <u>07-1392</u>.</p> <p>The Commissioner is hereby authorized to charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to our Deposit Account No. <u>07-1392</u>.</p>
---	---

DO NOT USE THIS SPACE

9. Statement and Signature.
To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Robert H. BRINK (36,094) Name of Person Signing	<u>Robert H. Brink (em)</u> Signature	<u>October 23, 2003</u> Date
--	--	---------------------------------

Total number of pages including cover sheet, attachments and document: 3

CH \$40.00 071392 10070084

PU3517

ASSIGNMENT

WHEREAS I/WE, **Pascal Maurice Charles PIANETTI** residing at Les Ulis, France, (hereinafter called "the inventor(s)") have invented or discovered "BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE" (hereinafter called "the invention") for which a patent application No. GB9920872.0 filed 4 September 1999 in the United Kingdom and for which an international PCT patent application is now being filed designating the **United States of America**. I/we hereby authorize and request that the filing date and PCT International application, when known, be inserted here in parentheses;

(PCT EP00/08487 filed 31 August 2000)

WHEREAS the invention, being made in the circumstances set out in Section 1ter(1) of the Patent Law in France, belongs to my/our employer, namely **LABORATOIRE GLAXOSMITHKLINE**, a company incorporated in France whose registered address is 100 route de Versaille, 78163 Marly-le-Roi, France, and

WHEREAS **SMITHKLINE BEECHAM CORPORATION**, a corporation organised and existing under and by virtue of the laws of the State of Pennsylvania and having its principal place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101 is desirous of acquiring from **LABORATOIRE GLAXOSMITHKLINE** the whole right, title and interest in and to the invention and the application in respect of the United States of America;


NOW, THEREFORE, to all whom it may concern be it known that I/we, the inventor(s), hereby confirm the ownership by **LABORATOIRE GLAXOSMITHKLINE** of the invention and the application by operation of law under the Patent Law of France and, if under the law of the United States of America I/we the inventor(s) have any ownership right, title and interest in the invention and the application (which I/we do not believe to be the case and claim no ownership right, title or interest in the invention and the application based on the law of the United Kingdom), I/we the inventor(s) nevertheless hereby assign and transfer such ownership right, title and interest in and to the invention and the application to **LABORATOIRE GLAXOSMITHKLINE** in turn hereby assigns and transfers to **SMITHKLINE BEECHAM CORPORATION** its whole right, title and interest in and throughout the United States of America in and to the invention and the application and in and to any priority rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in

rights in respect of the invention and the application and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension or re-issue thereof, and I/we the inventor(s) and LABORATOIRE GLAXOSMITHKLINE hereby authorise and request any patent arising therefrom in the United States of America be issued to SMITHKLINE BEECHAM CORPORATION.

AND LABORATOIRE GLAXOSMITHKLINE hereby, and I/we the inventor(s) for myself/ourselves and my/our respective executors and legal representatives hereby, agree to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in SMITHKLINE BEECHAM CORPORATION. its successors and assigns, the whole right, title and interest in and to the invention and the application hereby assigned and transferred in respect of the United States of America.


IT is hereby declared that each of the transactions hereby effected does not form part of a larger transaction or of a series of transactions in respect of which the amount or value, or the aggregate amount or value, of the consideration exceeds £60,000.

IN WITNESS whereof and with effect from the 4th Day of September 1999 the inventor(s) and David J. Levy as Attorney of LABORATOIRE GLAXOSMITHKLINE by virtue of Powers of Attorney granted by LABORATOIRE GLAXOSMITHKLINE respectively have hereunto set his respective hands.


X 
SIGNED by Pascal Maurice Charles PIANETTI:

X 28/09/02
Date:

in the presence of:

{ Witness to print name: Michael SIERRA
Witness to sign name: 

SIGNED by David J. Levy as the Attorney of each of LABORATOIRE GLAXOSMITHKLINE and SMITHKLINE BEECHAM CORPORATION:


David J. Levy, Attorney